HER2-Negative Breast Cancer Completed Phase 3 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00003440Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or MetastaticTreatment